Alzheimer's Therapeutics Market Report 2026-2036

The Alzheimer's Therapeutics Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Global Burden of Alzheimer's Disease Continues to Drive Market Demand

The persistent rise in global Alzheimer's disease prevalence continues to anchor long-term demand for therapeutics and sustained healthcare investment. Real-world evidence presented by Eisai and Biogen at AAIC 2025 showed that two years of continuous lecanemab (LEQEMBI®) treatment resulted in high rates of therapy continuation and relatively low discontinuation due to adverse events, reinforcing that real-world uptake remains strong despite clinical and logistical challenges. Commercially, this supports longer treatment durations per patient and strengthens lifetime-value models that increasingly favour disease-modifying therapies over short-course symptomatic care. The therapy's availability in more than 45 countries further amplifies this trend, prompting healthcare systems to plan for extended treatment regimens and encouraging payers to adopt long-horizon cost-effectiveness frameworks that account for earlier intervention and prolonged disease management.

What would be the Impact of US Trade Tariffs on the Global Alzheimer's Therapeutics Market?

U.S. trade tariffs would reshape the global Alzheimer's therapeutics market primarily by increasing upstream manufacturing and cross-border supply-chain costs rather than directly constraining finished-drug availability. Disease-modifying therapies-especially monoclonal antibodies-depend on globally distributed production networks spanning biologics drug-substance manufacturing, fill-finish operations, delivery-device assembly, specialised packaging, and cold-chain logistics. Much of this infrastructure sits in Europe and Asia, making the category highly sensitive to tariff-driven cost inflation. Higher landed costs in the U.S. would intensify payer scrutiny, slow reimbursement negotiations, and reinforce narrower patient-eligibility criteria for premium DMTs. For manufacturers, tariffs would compress margins and accelerate strategic shifts toward U.S.-based production, fill-finish localisation, and deeper reliance on domestic CDMOs-moves that raise capital intensity in the short term but reduce geopolitical exposure over time. Globally, these pressures could delay launch sequencing in secondary markets, divert investment away from smaller innovators with limited pricing flexibility, and widen access disparities between the U.S. and cost-sensitive regions. Rather than triggering a demand shock, tariffs would function as a structural cost and access headwind, reshaping competitive strategy, manufacturing footprints, and payer behaviour across the Alzheimer's therapeutics landscape.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Alzheimer's Therapeutics market evolving?
• What is driving and restraining the Alzheimer's Therapeutics market?
• How will each Alzheimer's Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
• How will the market shares for each Alzheimer's Therapeutics submarket develop from 2026 to 2036?
• What will be the main driver for the overall market from 2026 to 2036?
• Will leading Alzheimer's Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Alzheimer's Therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2026 and 2036? What are the implications of Alzheimer's Therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Alzheimer's Therapeutics market?
• Where is the Alzheimer's Therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Alzheimer's Therapeutics market today, and over the next 10 years:

• Our 269-page report provides 102 tables and 176 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2036 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Combination Drugs
• Others

Type of Treatment

• Symptomatic
• Disease-Modifying Therapies (DMTs)

Route of Administration

• Oral
• Injectable
• Transdermal

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Alzheimer's Therapeutics Market, 2026 to 2036, with a focus on this segment of these companies'operations.

Leading companies and the potential for market growth

• AbbVie Inc.
• AC IMMUNE SA
• Biogen
• Eisai Inc.
• GSK plc
• Grifols, S.A.
• Janssen Pharmaceutica NV
• Neurim Pharmaceuticals LTD.
• Novo Nordisk
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Merck & Co., Inc.

Overall world revenue for Alzheimer's Therapeutics Market, 2026 to 2036 in terms of value the market will surpass US$6.0 billion in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Alzheimer's Therapeutics Market, 2026 to 2036 report help you?

In summary, our 290+ page report provides you with the following knowledge:

• Revenue forecasts to 2036 for Alzheimer's Therapeutics Market 2026 to 2036, with forecasts for Drug Class, Type of Treatment, Route of Administration, Distribution Channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2036 for five regional and 19 key national markets - See forecasts for the Alzheimer's Therapeutics Market, 2026 to 2036 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Alzheimer's Therapeutics Market, 2026 to 2036.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment. Show more